Core Insights - KRAS is one of the most mutated cancer driver genes, traditionally considered "undruggable" due to its smooth surface and high affinity for GTP/GDP, but recent advancements in targeting specific mutations like KRAS G12C have shown some progress [1] - Insilico Medicine (03696) is developing a pan-KRAS inhibitor strategy that targets multiple key mutations, with the oral small molecule ISM6166 showing promise for treating various KRAS-driven solid tumors such as lung, pancreatic, colorectal, and gastric cancers [1] - ISM6166 has demonstrated significant tumor suppression and regression effects in preclinical studies while maintaining high selectivity and favorable pharmacokinetic properties, indicating a balanced drug-like profile [1] Efficacy Data - In lung cancer models, ISM6166 achieved an 86.2% tumor growth inhibition rate (TGI) at a dose of 10 mg/kg and a 55.1% tumor regression at 30 mg/kg [2] - In gastric cancer models, ISM6166 showed even more pronounced anti-tumor efficacy, with a TGI of 99.5% at 5 mg/kg and up to 65.8% tumor regression at higher doses [2] Selectivity and Pharmacokinetics - ISM6166 maintains high selectivity for other RAS family proteins, which is crucial for reducing off-target toxicity and potential side effects [4] - The compound has shown good plasma clearance rates and acceptable oral bioavailability across four preclinical species, supporting its potential as a best-in-class oral therapy [4] Research Background - This is not the first time Insilico Medicine has leveraged its AI capabilities in the "undruggable" space; in 2025, the company was recognized in the Nature Biotechnology's top ten research advancements for its KRAS-related studies, which combined quantum and classical computing methods for small molecule design [4]
AI突破“不可成药” 英矽智能泛KRAS抑制剂ISM6166实现临床前肿瘤消退